- call +1-201-465-4211
- email sales@mrinsights.biz
Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
Scope of the Report:
The global Immuno-Oncology market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Immuno-Oncology.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Immuno-Oncology market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Immuno-Oncology market by product type and applications/end industries.
Market Segment by Companies, this report covers
Amgen, Inc
AstraZeneca, Plc
Bristol-Myers Squibb
Celgene Corporation
Eli Lilly and Company
Merck & Co.
Hoffmann-La Roche AG
Johnson & Johnson
Novartis International AG
AbbVie
Pfizer Inc.
Sanofi S.A.
EMD Serono
Gilead Sciences Inc.
Prometheus Therapeutics & Diagnostics
Aduro BioTech
Galena Biopharma
Bavarian Nordic
Celldex Therapeutics
ImmunoCellular Therapeutics
Incyte
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Immune Checkpoint Inhibitors
Monoclonal Antibodies
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Market Segment by Applications, can be divided into
Hospitals
Pharmacies
Online Pharmacies
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Immuno-Oncology Market Overview
1.1 Product Overview and Scope of Immuno-Oncology
1.2 Classification of Immuno-Oncology by Types
1.2.1 Global Immuno-Oncology Revenue Comparison by Types (2017-2023)
1.2.2 Global Immuno-Oncology Revenue Market Share by Types in 2017
1.2.3 Immune Checkpoint Inhibitors
1.2.4 Monoclonal Antibodies
1.2.5 Cytokine-Based Immunotherapy
1.2.6 Cancer Vaccines
1.2.7 CAR-T Cell Therapy
1.3 Global Immuno-Oncology Market by Application
1.3.1 Global Immuno-Oncology Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Pharmacies
1.3.4 Online Pharmacies
1.4 Global Immuno-Oncology Market by Regions
1.4.1 Global Immuno-Oncology Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Immuno-Oncology Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Immuno-Oncology Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Immuno-Oncology Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Immuno-Oncology Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Immuno-Oncology Status and Prospect (2013-2023)
1.5 Global Market Size of Immuno-Oncology (2013-2023)
2 Manufacturers Profiles
2.1 Amgen, Inc
2.1.1 Business Overview
2.1.2 Immuno-Oncology Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Amgen, Inc Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.2 AstraZeneca, Plc
2.2.1 Business Overview
2.2.2 Immuno-Oncology Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 AstraZeneca, Plc Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.3 Bristol-Myers Squibb
2.3.1 Business Overview
2.3.2 Immuno-Oncology Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Bristol-Myers Squibb Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.4 Celgene Corporation
2.4.1 Business Overview
2.4.2 Immuno-Oncology Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Celgene Corporation Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.5 Eli Lilly and Company
2.5.1 Business Overview
2.5.2 Immuno-Oncology Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Eli Lilly and Company Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.6 Merck & Co.
2.6.1 Business Overview
2.6.2 Immuno-Oncology Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Merck & Co. Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.7 Hoffmann-La Roche AG
2.7.1 Business Overview
2.7.2 Immuno-Oncology Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Hoffmann-La Roche AG Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.8 Johnson & Johnson
2.8.1 Business Overview
2.8.2 Immuno-Oncology Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Johnson & Johnson Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.9 Novartis International AG
2.9.1 Business Overview
2.9.2 Immuno-Oncology Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Novartis International AG Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.10 AbbVie
2.10.1 Business Overview
2.10.2 Immuno-Oncology Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 AbbVie Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.11 Pfizer Inc.
2.11.1 Business Overview
2.11.2 Immuno-Oncology Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Pfizer Inc. Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.12 Sanofi S.A.
2.12.1 Business Overview
2.12.2 Immuno-Oncology Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Sanofi S.A. Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.13 EMD Serono
2.13.1 Business Overview
2.13.2 Immuno-Oncology Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 EMD Serono Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.14 Gilead Sciences Inc.
2.14.1 Business Overview
2.14.2 Immuno-Oncology Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Gilead Sciences Inc. Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.15 Prometheus Therapeutics & Diagnostics
2.15.1 Business Overview
2.15.2 Immuno-Oncology Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Prometheus Therapeutics & Diagnostics Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.16 Aduro BioTech
2.16.1 Business Overview
2.16.2 Immuno-Oncology Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Aduro BioTech Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.17 Galena Biopharma
2.17.1 Business Overview
2.17.2 Immuno-Oncology Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Galena Biopharma Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.18 Bavarian Nordic
2.18.1 Business Overview
2.18.2 Immuno-Oncology Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Bavarian Nordic Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.19 Celldex Therapeutics
2.19.1 Business Overview
2.19.2 Immuno-Oncology Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Celldex Therapeutics Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.20 ImmunoCellular Therapeutics
2.20.1 Business Overview
2.20.2 Immuno-Oncology Type and Applications
2.20.2.1 Product A
2.20.2.2 Product B
2.20.3 ImmunoCellular Therapeutics Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
2.21 Incyte
2.21.1 Business Overview
2.2.2 Immuno-Oncology Type and Applications
2.21.2.1 Product A
2.21.2.2 Product B
2.21.3 Incyte Immuno-Oncology Revenue, Gross Margin and Market Share (2016-2017)
3 Global Immuno-Oncology Market Competition, by Players
3.1 Global Immuno-Oncology Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Immuno-Oncology Players Market Share
3.2.2 Top 10 Immuno-Oncology Players Market Share
3.3 Market Competition Trend
4 Global Immuno-Oncology Market Size by Regions
4.1 Global Immuno-Oncology Revenue and Market Share by Regions
4.2 North America Immuno-Oncology Revenue and Growth Rate (2013-2018)
4.3 Europe Immuno-Oncology Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Immuno-Oncology Revenue and Growth Rate (2013-2018)
4.5 South America Immuno-Oncology Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Immuno-Oncology Revenue and Growth Rate (2013-2018)
5 North America Immuno-Oncology Revenue by Countries
5.1 North America Immuno-Oncology Revenue by Countries (2013-2018)
5.2 USA Immuno-Oncology Revenue and Growth Rate (2013-2018)
5.3 Canada Immuno-Oncology Revenue and Growth Rate (2013-2018)
5.4 Mexico Immuno-Oncology Revenue and Growth Rate (2013-2018)
6 Europe Immuno-Oncology Revenue by Countries
6.1 Europe Immuno-Oncology Revenue by Countries (2013-2018)
6.2 Germany Immuno-Oncology Revenue and Growth Rate (2013-2018)
6.3 UK Immuno-Oncology Revenue and Growth Rate (2013-2018)
6.4 France Immuno-Oncology Revenue and Growth Rate (2013-2018)
6.5 Russia Immuno-Oncology Revenue and Growth Rate (2013-2018)
6.6 Italy Immuno-Oncology Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Immuno-Oncology Revenue by Countries
7.1 Asia-Pacific Immuno-Oncology Revenue by Countries (2013-2018)
7.2 China Immuno-Oncology Revenue and Growth Rate (2013-2018)
7.3 Japan Immuno-Oncology Revenue and Growth Rate (2013-2018)
7.4 Korea Immuno-Oncology Revenue and Growth Rate (2013-2018)
7.5 India Immuno-Oncology Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Immuno-Oncology Revenue and Growth Rate (2013-2018)
8 South America Immuno-Oncology Revenue by Countries
8.1 South America Immuno-Oncology Revenue by Countries (2013-2018)
8.2 Brazil Immuno-Oncology Revenue and Growth Rate (2013-2018)
8.3 Argentina Immuno-Oncology Revenue and Growth Rate (2013-2018)
8.4 Colombia Immuno-Oncology Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Immuno-Oncology by Countries
9.1 Middle East and Africa Immuno-Oncology Revenue by Countries (2013-2018)
9.2 Saudi Arabia Immuno-Oncology Revenue and Growth Rate (2013-2018)
9.3 UAE Immuno-Oncology Revenue and Growth Rate (2013-2018)
9.4 Egypt Immuno-Oncology Revenue and Growth Rate (2013-2018)
9.5 Nigeria Immuno-Oncology Revenue and Growth Rate (2013-2018)
9.6 South Africa Immuno-Oncology Revenue and Growth Rate (2013-2018)
10 Global Immuno-Oncology Market Segment by Type
10.1 Global Immuno-Oncology Revenue and Market Share by Type (2013-2018)
10.2 Global Immuno-Oncology Market Forecast by Type (2018-2023)
10.3 Immune Checkpoint Inhibitors Revenue Growth Rate (2013-2023)
10.4 Monoclonal Antibodies Revenue Growth Rate (2013-2023)
10.5 Cytokine-Based Immunotherapy Revenue Growth Rate (2013-2023)
10.6 Cancer Vaccines Revenue Growth Rate (2013-2023)
10.7 CAR-T Cell Therapy Revenue Growth Rate (2013-2023)
11 Global Immuno-Oncology Market Segment by Application
11.1 Global Immuno-Oncology Revenue Market Share by Application (2013-2018)
11.2 Immuno-Oncology Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Pharmacies Revenue Growth (2013-2018)
11.5 Online Pharmacies Revenue Growth (2013-2018)
12 Global Immuno-Oncology Market Size Forecast (2018-2023)
12.1 Global Immuno-Oncology Market Size Forecast (2018-2023)
12.2 Global Immuno-Oncology Market Forecast by Regions (2018-2023)
12.3 North America Immuno-Oncology Revenue Market Forecast (2018-2023)
12.4 Europe Immuno-Oncology Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Immuno-Oncology Revenue Market Forecast (2018-2023)
12.6 South America Immuno-Oncology Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Immuno-Oncology Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Immuno-Oncology Picture
Table Product Specifications of Immuno-Oncology
Table Global Immuno-Oncology and Revenue (Million USD) Market Split by Product Type
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
